Cells of the acute myeloid leukemia (AML) t(8;21) subtype express the B-lymphoid lineage marker Paired Box 5 (PAX5), and frequently, but not always, express the characteristically B-lymphoid surface markers CD19 and CD79a.
Cells of the acute myeloid leukemia (AML) t(8;21) subtype express the B-lymphoid lineage marker Paired Box 5 (PAX5), and frequently, but not always, express the characteristically B-lymphoid surface markers CD19 and CD79a. 1 --3 However, mechanisms for activation of this 'B-lineage' program and its potential contribution to the transformation process are unclear.
Comprehensive studies of the t(8;21) translocation product AML1/ETO (also known as RUNX1/RUNX1T1 or AML1/MTG8) have identified its sufficiency in inhibition of myeloid gene function and immortalisation of both human and murine progenitors, however AML1/ETO alone is insufficient for leukemogenesis, suggesting it requires co-operating events to drive disease. 4 The POU homeobox gene POU4F1 (also known as BRN3A) is highly expressed in t(8;21) samples, with AML1/ETO appearing both to promote some BRN3A expression and co-operate with its protein product Brn3a to restrict myeloid gene expression. 5, 6 An ability of Brn3a shRNA to impair AML1/ETO-dependent immortalisation of murine haematopoietic progenitor cells in vitro suggests an important role for BRN3A in the human disease. 6 The aim of the present study was to investigate potential control of B-lineage gene expression by AML1/ETO and BRN3A in Letters to the Editor both ex vivo t(8;21) AML samples and murine haematopoietic progenitor cells in vitro.
Informed written consent was obtained before storing of patient samples. Initially, significantly higher expression of B-lineage genes PAX5, early B cell factor 1 (EBF1) and CD19 in 10 t(8;21) AML patient samples compared with 7 normal karyotype (NK) AML samples was confirmed in our own microarray data set (Figure 1a ). High expression of both ETO and POU4F1 transcripts confirmed cytogenetic diagnosis of t(8;21) samples, whereas NFIL3, recently identified as an NK-cell gene, potential B-lineage inhibitor and target for E2a repression 7 --9 was significantly underexpressed in t(8;21) samples.
To investigate whether B-lineage gene expression in t(8;21) AML samples might be controlled by AML1/ETO, this factor was depleted from primary t(8;21) AML cells by siRNA and gene expression monitored. AML1/ETO reduction significantly decreased both PAX5 and EBF1 transcript levels 24 h after siRNA treatment, which was maintained at 48 and 72 h timepoints ( Figure 1b) . In converse experiments in murine foetal liver haematopoietic progenitors cultured under myeloid cytokine conditions (interleukin (IL)-3, IL-6, stem cell factor (SCF) and granulocyte-monocyte colony stimulating factor (GM-CSF)), expressions of Ebf1 and Pax5 but not E2a were moderately increased (mean±s.d. 5.7±3.4, 4.6±1.2 and 1.1±0.3-fold, respectively) 48 h after transduction with AML1/ETO9a retrovirus ( Figure 1c ). Both systems indicated limited ability of AML1/ETO to reduce NFIL3/Nfil3 expression.
To examine the importance of appropriate B-lineage transcription factor expression for AML1/ETO-dependent immortalisation, retroviruses expressing Pax5 shRNA or Nfil3 cDNA were constructed and co-transduced into progenitors alongside AML1/ETO, and semi-solid methylcellulose replating assays performed. Significantly, ectopic Nfil3 expression or reduction of Pax5 expression by the most efficient shPax5 virus induced loss of hCD2 positivity --/c-Kit þ haematopoietic progenitor cell co-transduction with pMIG-A/E9a alongside either shRNA-hCD2 (control), shPax5 (#2) or Nfil3 retroviruses, at the indicated timepoints after transduction (methylcellulose semisolid M3434 culture supplemented with 10 ng/ml GM-CSF initiated at day 2). Numbers indicate percentage contribution of each GFP þ quadrant to total viable cell count. from AML1/ETO (green fluorescent protein (GFP) þ ) populations in semi-solid culture (Figure 1d ). In liquid cultures established from third round replating, remaining shPax5/AE double-transduced cells showed marked impairment in growth compared with controls (data not shown), whereas Nfil3/AE-transduced cultures had almost no hCD2 þ /GFP þ cells remaining at this time.
Parallel t(8;21) AML subtype-specific expressions of POU4F1/ BRN3A, PAX5 and EBF1 prompted us to examine a potential role for BRN3A in B-lineage gene expression in t(8;21) AML. Initially, we attempted to target BRN3A expression by siRNA in patient samples, but despite using duplexes validated in cell lines, and patient samples in which AML1/ETO siRNA was efficient (suggesting intact siRNA machinery) this was repeatedly unsuccessful (data not shown). Our efforts were thus focused on experiments with murine foetal liver haematopoietic progenitors. Expression of AML1/ETO in such progenitors moderately increases Brn3a expression 6 but not to the markedly high levels observed in t(8;21) AML samples. Therefore, to examine a potential combined role for AML1/ETO and robust BRN3A expression in B-lymphoid gene control, co-infection experiments were performed using retroviruses containing GFP or human CD2 tailess (hCD2) marker genes.
Progenitors were doubly transduced under myeloid cytokine conditions (SCF 100 ng/ml, and IL-3, IL-6, GM-CSF all 10 ng/ml) with either (i) GFP and hCD2, (ii) AML1/ETO9a and hCD2, (iii) GFP and Brn3a-hCD2 or (iv) AML1/ETO9a and Brn3a-hCD2 viruses, and sorted 48 h after transduction for analysis of B-lymphoid gene expression (Figures 2a and b) . Remarkably, populations co-transduced with AML1/ETO and Brn3a retroviruses exhibited mean 50-fold and 20-fold increases in expressions of Ebf1 and Pax5, respectively. Co-transduction of AML1/ETO9a and hCD2 alone conferred moderate (two to fivefold) increases in Ebf1 and E2a transcript levels but not Pax5 as in previous single transduction experiments, possibly due to reduced expression of AML1/ETO in double versus single transductions. Although Brn3a inhibited Pax5 and Ebf1 expression efficiently in lymphoidcultured progenitors (unpublished data), it did not regulate B-lineage gene expression significantly under myeloid conditions (Figure 2b) . Neither Brn3a alone, AML1/ETO alone, nor both together were able to repress low basal Nfil3 expression, although interestingly the AML1/ETO plus Brn3a combination activated Tle1.
Importantly, synergistic activation of Ebf1 could be confirmed at the protein level (Figure 2c) . In silico analysis of Ebf/EBF1 and Pax5/ PAX5 regulatory regions indicated that synergistic AML1/ETO and BRN3A action is likely to be mediated via multiple adjacent predicted binding sites in both human and murine genes (Figure 2d) , with the structural similarity between human and murine Ebf1/EBF1 and the presence of a potential duplicated AML-binding site 10 in human EBF1 of particular note. Double-transduced progenitors expressing AML1/ETO and high Brn3a display myeloid blast morphology at the first round of replating, 6 and productive expression of B-lymphoid surface markers was not anticipated. Although induction of CD19 transcripts was reliably observed, most significantly at day 6 post-transduction (Figure 2e ), CD19 protein production at this time was generally not (Figure 2c ). However, in one experiment (of five), flow cytometric analysis showed B36% expression of CD19 in double-transduced populations (data not shown).
PAX5 expression in t(8;21) AML blasts is well-established, 2,11 and here we have shown also increased EBF and consistently reduced NFIL3 expression in t(8;21) AML, suggesting that a transcription factor combination conducive to early B-cell development is required in this disease. Analysis of primary t(8;21) samples suggests that a range of combinations are possible, some with very high PAX5, some with very high EBF1 and most with low NFIL3 expression. The importance of this transcription factor equilibrium is highlighted by our finding that either Pax5 reduction or Nfil3 overexpression impairs AML1/ETO-dependent immortalisation of myeloid progenitors, and likely results from promotion of cellular maintenance or 'stem-cell' functions, as established previously for Pax5, 12 rather than normal cellular B-cell type functions. Furthermore, as Pax5 is a robust repressor of myeloid lineage via genes such as c-fms, 13 potential PAX5 activation by AML1/ETO provides an indirect pathway for inhibition of myeloid development complementary to direct CEBPA and PU.1 repression pathways.
Our data suggest strongly that EBF and possibly PAX5 expression in t(8;21) results from direct BRN3A and AML1/ETO synergy. Importantly, such AML1/ETO and/or Brn3a functional effects appear to be clear in sorted murine hematopoietic progenitors (for example, 6 and this study) but not in unsorted bone marrow, 14 suggesting cell-type specific action of Brn3a, as previously described for AML1/ETO. Also, there are indications from our patient data set that blast populations with similar AML1-ETO/BRN3A expression profiles have similar B-lineage expression profiles (Figure 1a , compare t(8;21) samples 2 and 10, compare 3 and 9 and compare 4, 6 and 8). Importantly, the murine co-transduction system presents an accessible in vitro model for study of B-lymphoid transcription factor expression in AML1/ETOpositive cells, which has been lacking thus far.
A recent study has implicated PAX5 to be important for CD19 transcription in t(8;21) AML blasts, 11 and we found AML1/ETO plus Brn3a co-transduction to increase both Pax5 and Cd19 transcripts. However, CD19 protein induction in our model was variable, consistent with CD19 immuno-negativity in some t(8;21) AML cases. Also, when AML1/ETO plus Brn3a cultures did display B-lymphoid surface marker expression at the first round of replating, this was not maintained in immortalising populations at the second round of replating. These discrepancies between CD19 protein expression and t(8;21) immortalisation/transformation perhaps support the hypothesis that B-lineage transcription factors rather than surface markers are most important in t(8;21) AML.
In summary, these findings implicate enhanced BRN3A expression as a 'second-hit' required in addition to AML1/ETO for EBF and PAX5 activation in t(8;21) AML. Interestingly, TLE1 induction may represent a potentially deleterious side-effect of AML1/ETO and BRN3A synergy, which is overcome by TLE1 gene loss (third hit) during t(8;21) AML development. 15 It will be important to identify which additional factors co-operate with AML1/ETO to produce high BRN3A expression in t(8;21) AML, and to examine how widespread is AML1/ETO --BRN3A synergy. Yoshida et al. 1 recently described recurrent somatic mutations that involved different components of the RNA splicing machinery and other spliceosome-related genes in 209 of 582 patients with myeloid neoplasms: 228 with myelodysplastic syndromes (MDS) with (n ¼ 73) or without (n ¼ 155) ring sideroblasts (RS), 88 with chronic myelomonocytic leukemia (CMML), 151 with primary acute myeloid leukemia (AML), 62 with AML that is therapy-related or displayed MDS-like features (t-AML/MDS) and 53 with myeloproliferative neoplasms (MPN). Mutational frequencies were B85% in MDS-RS, 44% in MDS without RS, 55% in CMML, 26% in t-AML/MDS, 7% in primary AML and 9% in MPN. In MDS-RS, the most frequent (75.3%) spliceosome mutations involved splicing factor 3B subunit 1 (SF3B1) with mutational frequencies of 83% in refractory anemia with RS (RARS) and 76% in refractory cytopenia with multilineage dysplasia-RS. SF3B1 mutations were less frequent in MDS without RS (6.5%) or other myeloid neoplasms (o5%); none of the MPN cases displayed SF3B1 mutations. Mutations involving the serine/arginine-rich (SR) protein, SRSF2, were more frequent in CMML (28.4%), MDS without RS (11.6%) or t-AML/MDS (6.5%). The authors also described other spliceosome component mutations that involved genes encoding for U2 auxiliary factor small nuclear ribonucleoprotein (snRNP) complexes including U2AF35 and U2AF65, zinc finger, RNA-binding motif and serine/arginine-rich (SR) protein 2 (ZRSR2), SF3A1, SF1 and PRP40 pre-mRNA processing factor 40 homolog B (PRPF40B).
1 These mutations were mutually exclusive and their common functional consequence is believed to involve global abnormalities in RNA splicing, resulting in reduced cell proliferation and increased apoptosis. 1 SF3B1 (located on chromosome 2q33.1) mutations in MDS-RS have also been reported by Papaemmanuil et al. 2 and Visconte et al. 3 At the time of this writing, details regarding the former study 2 were not available, whereas in the latter study 3 heterozygous SF3B1 mutations were reported in 9 (64%) of 14 patients with RARS, 13 (72%) of 18 patients with RARS and marked thrombocytosis (RARS-T), and none of 24 patients with MDS/MPN without RS. 3 The most common SF3B1 mutation reported by Visconte et al. 3 was SF3B1K700E (64%); other mutations described by these authors involved K666 (n ¼ 3), R625 (n ¼ 2), E622 (n ¼ 1), H662 (n ¼ 1) and del699-700QK (n ¼ 1). In the aforementioned study by Yoshida et al.,
1 SF3B1 mutations also involved K700, K666, H662 and E622. Visconte et al. 3 demonstrated that JAK2, MPL, LNK or DNMT3A mutations can co-occur with SF3B1 mutations and suggested an association between SF3B1 mutations and thrombosis. 3 The objective of the current study was to define the prevalence of SF3B1 mutations in chronic-phase primary myelofibrosis (PMF) and investigate its prognostic relevance and phenotypic correlates. We were particularly interested in the presence or absence of bone marrow RS in SF3B1-mutated cases and whether or not the reported association with thrombosis can be confirmed.
The current study was approved by the Mayo Clinic institutional review board. Study patients were recruited from Mayo Clinic databases of patients with PMF in whom complete clinical and laboratory information was available and in whom stored DNA was available for SF3B1 mutation screening. In SF3B1-mutated patients, bone marrow pathology slides, including iron stains, were centrally re-reviewed in order to confirm morphological diagnosis and to quantify bone marrow RS percentage. Detailed analysis of clinical parameters and cytogenetic findings was performed to risk stratify patients according to the Dynamic International Prognostic Scoring System (DIPSS)-plus. 4 All patients were also screened for JAK2, MPL and IDH mutations, using previously described methods.
--7
SF3B1-coding exon sequencing was performed using bone marrow-or granulocyte-derived DNA extract (Qiagen, Valencia, CA, USA). Individual mutations were examined and excluded for occurrence in normal genetic variation by interrogation of the NCBI single-nucleotide polymorphism (dbSNP) database. All products were confirmed by 1% agarose gel, purified using QIAquick Spin Kit (Qiagen, Santa Clarita, CA, USA) and submitted for sequencing using two ABI PRISM 3730xl DNA Analyzers (Applied Biosystems Inc., Foster City, CA, USA) (96-capillary). In order to confirm previous observations and to determine regions of frequent mutation occurrence, we first sequenced all SF3B1-coding exons in 10 RARS cases and identified six patients with SF3B1 mutations that clustered in exons 14 and 15 (data not shown). Accordingly, only exons 13 --15 were sequenced in our study patients with PMF; 50 --100 ng DNA was added to a 50 ml final volume mixture of: 5 ml 10 Â PCR Buffer (Roche Diagnostics, Indianapolis, IN, USA), 1.5 ml of dNTP (10 mM of each), 0.5 ml of Taq Polymerase (Roche Diagnostics), and 2 ml each of a 10 mM stock of forward (SH3B1 FP 5 0 -TAGAGTGGAAGGCCGAGAGA-3 0 ) and reverse (SH3B1 RP 5 0 -TTCAAGAAAGCAGCCAAACC-3 0 ) primers, supplemented with PCR grade water. Parameters for this PCR amplification included an initial denaturation step of 95 1C for 2 min, followed by 35 cycles of an initial melt at 95 1C for 15 s, annealing at 60 1C for 45 s, extension at 72 1C for 1:10 min and a final extension step of 72 1C for 3 min. The products were purified with QIAquick Spin Kit (Qiagen). Sequencing was performed bidirectionally. Standard statistical methods were used for parameter comparison and survival curves were prepared by the Kaplan --Meier method and compared by the log-rank test. P-values o0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all analyses.
A total of 155 patients were studied and their clinical and laboratory characteristics are listed in 
